Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30‐positive Hodgkin's lymphoma or systemic anaplastic large‐cell lymphoma
Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Ishizawa, Kenichi, Uike, Naokuni, Uchida, Toshiki, Suzuki, Tatsuya, Aoki, Tomohiro, Watanabe, Takashi, Maruyama, Dai, Yokoyama, Masahiro, Takubo, Takatoshi, Kagehara, Hideaki, Matsushima, Takafumi
Published in Cancer science (01.07.2014)
Published in Cancer science (01.07.2014)
Get full text
Journal Article
245 Development and application of physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model for dose optimization of TAK-102: GPC3 targeted CAR-T armored with IL-7 and CCL-19
Dey, Agnish, Kagehara, Hideaki, Pop-Damkov, Petar, Sumi, Eriko, Maeda, Eiki, Akaike, Takenori, Atkuri, Kondala, Suzuki, Kotaro, Ochi, Masashi, Koyama, Takafumi, Kuboki, Yasutoshi, Nakajima, Takako Eguchi, Mugundu, Ganesh M, Singh, Aman
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
O6-3 Interim results of FIH phase 1 of TAK-102, GPC-3 targeted armored CAR-T therapy in patients with advanced solid tumors
Kuboki, Yasutoshi, Shimizu, Toshio, Doi, Toshihiko, Yamamoto, Noboru, Kondo, Shunsuke, Okal, Abood, Singh, Aman, Markman, Janet, Akaike, Takenori, Kagehara, Hideaki, Koyama, Takafumi
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
Phase I / II study of brentuximab vedotin in J apanese patients with relapsed or refractory CD 30‐positive H odgkin's lymphoma or systemic anaplastic large‐cell lymphoma
Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Ishizawa, Kenichi, Uike, Naokuni, Uchida, Toshiki, Suzuki, Tatsuya, Aoki, Tomohiro, Watanabe, Takashi, Maruyama, Dai, Yokoyama, Masahiro, Takubo, Takatoshi, Kagehara, Hideaki, Matsushima, Takafumi
Published in Cancer science (01.07.2014)
Published in Cancer science (01.07.2014)
Get full text
Journal Article
Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity
SATOH, Motonobu, TSURUMAKI, Kazusa, KAGEHARA, Hideaki, YAMAZAKI, Masatoshi
Published in Cancer Immunology, Immunotherapy (01.02.2002)
Published in Cancer Immunology, Immunotherapy (01.02.2002)
Get full text
Journal Article